Breaking News, Collaborations & Alliances

BioVaxys & Sona Nanotech Enter Research Collaboration

The agreement will develop new cancer therapeutics that combine BioVaxys' DPX Platfrom and Sona’s THT.

By: Rachel Klemovitch

Assistant Editor

BioVaxys Technology Corp. (BioVaxys) and Sona Nanotech Inc. (Sona) have entered a Research Agreement to develop new cancer therapeutics based on BioVaxys’ DPX Immune Educating Platform (DPX) with Sona’s Targeted Hyperthermia Therapy (THT).  THT is a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona’s biocompatible Gold Nanorod (GNR) technology, whic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters